Brief: Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease
05/06/2026 11:42
BRIEF-Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease June 5 (Reuters) - Bayer AG BAYGn.DE:
PHASE III FIND‑CKD RESULTS SHOW BAYER’S KERENDIA® (FINERENONE) IMPROVED EGFR SLOPE AND REDUCED RISK OF A COMPOSITE KIDNEY-CARDIOVASCULAR OUTCOME IN ADULTS WITH NON‑DIABETIC CHRONIC KIDNEY DISEASE
BAYER AG - KERENDIA MEETS PRIMARY ENDPOINT WITH SIGNIFICANT REDUCTION IN KIDNEY DISEASE PROGRESSION
BAYER AG - KERENDIA SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES; SERIOUS ADVERSE EVENTS 20.9% VERSUS 21.2% PLACEBO
BAYER AG - KERENDIA REDUCES RISK OF COMPOSITE KIDNEY-CARDIOVASCULAR OUTCOME VERSUS PLACEBO
Source text: ID:nBw6wPtQ3a
Further company coverage: [BAYGn.DE]
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bayer AG
See all newsBrief: Bayer Says Finerenone Slowed Kidney Decline In CKD
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant
Deutsche Bank AG FF - Post Stabilisation Notice -Bayer EUR 30NC6 & 30NC9
Brief: Bayer To Present New Finerenone Data Across Chronic Kidney Disease With And Without Diabetes At Asn Kidney Week 2026
Brief: FDA Approves Once-Weekly Generic Hormone Therapy Patch For Women